Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Pierluigi Porcu"'
Autor:
Felipe Suarez, Hun Ju Lee, Cliona M. Rooney, Daniel Y Lee, Helen E. Heslop, Hye Jin Kang, Dok Hyun Yoon, Shannon Inman, Kirit M. Ardeshna, Cheolwon Suh, Pierluigi Porcu, Katherin E Combs, Seok Jin Kim, Arnaud Jaccard, Ranjana H. Advani, Yasuhiro Oki, Catherine M. Bollard, Yi Lin, Jin Seok Kim, Eric D. Jacobsen, Maryann Murray, Kurt C. Gunter, Emmanuel Bachy, John Radford, Jonathan E. Brammer, Jia Ruan, Lihua E. Budde, Sang Eun Yoon, Won Seog Kim
Publikováno v:
Annals of Hematology. 100:2529-2539
We conducted a phase II clinical trial to develop an autologous EBV-specific T cell product (baltaleucel T) for advanced, relapsed ENKTL. Among 47 patients who provided whole blood starting material for manufacturing the product, 15 patients received
Autor:
Doaa Shalabi, Joya Sahu, Pierluigi Porcu, Jisun Cha, Wenyin Shi, Neda Nikbakht, Megan O'Donnell, Seyfettin Onder Alpdogan, Saritha Kartan
Publikováno v:
Journal of the American Academy of Dermatology. 84:615-623
Background Topical corticosteroids alone or in combination with other therapies are widely used to treat mycosis fungoides (MF), but data on response rates to their use as monotherapy in MF are limited. Objective To evaluate the efficacy of topical c
Autor:
Pierluigi Porcu, Neil Palmisiano, Dolores Grosso, Joanne Filicko-O'Hara, Thomas R. Klumpp, Ubaldo E. Martinez-Outschoorn, John L. Wagner, Matthew Carabasi, Usama Gergis, Shannon Rudolph, Maria Werner-Wasik, Neal Flomenberg, William O'Hara, Margaret Kasner, Lindsay Wilde, Wenyin Shi, Beth W. Colombe, Adam F. Binder, Michael Sun, Onder Alpdogan
Publikováno v:
Biology of Blood and Marrow Transplantation. 26:1861-1867
The use of cyclophosphamide (CY) for bidirectional tolerization of recipient and donor T cells is associated with reduced rates of graft-versus-host disease (GVHD) and nonrelapse mortality (NRM) after HLA-matched hematopoietic stem cell transplantati
Autor:
Michael Chang, Pierluigi Porcu, Li-Anne S Lim, Arman Mashayekhi, Lauren A Dalvin, Nina L. Martinez, Mehdi Mazloumi, Carol L. Shields, David Ancona-Lezama, Jon Glass
Publikováno v:
Asia-Pacific Journal of Ophthalmology. 9:110-116
Purpose The aim of this study was to identify clinical factors predictive of time to central nervous system (CNS) lymphoma or death in patients with vitreoretinal lymphoma (VRL). Design Retrospective cohort study. Methods Patients with VRL (n = 95 pa
Autor:
Kami J. Maddocks, Beth Christian, Amelia Langston, Mary Jo Lechowicz, Lai Wei, Steven M. Devine, Kristie A. Blum, Leonard T. Heffner, Christopher R. Flowers, Pierluigi Porcu, Jonathon B. Cohen
Publikováno v:
Cancer. 126:1235-1242
Background Both gemcitabine and bendamustine have been evaluated in patients with recurrent/refractory Hodgkin lymphoma but to the authors' knowledge not as a doublet. The authors completed a phase 1/2 trial to identify the optimal dose and frequency
Autor:
Maarten H. Vermeer, Martine Bagot, Federico Rotolo, Cécile Bonnafous, Hélène Sicard, Anne Marie-Cardine, Hatem A. Azim, Caroline Ram-Wolff, Sean Whittaker, Maxime Battistella, Michael S. Khodadoust, Carine Paturel, Armand Bensussan, Pierluigi Porcu, Basem M. William, Youn H. Kim
Publikováno v:
Lancet Oncology
Lancet Oncology, Elsevier, 2019, 20 (8), pp.1160-1170. ⟨10.1016/S1470-2045(19)30320-1⟩
Lancet Oncology, Elsevier, 2019, 20 (8), pp.1160-1170. ⟨10.1016/S1470-2045(19)30320-1⟩
Summary Background IPH4102 is a first-in-class monoclonal antibody targeting KIR3DL2, a cell surface protein that is expressed in cutaneous T-cell lymphoma, and predominantly in its leukaemic form, Sezary syndrome. We aimed to assess the safety and a
Autor:
Steven Horwitz, Owen A O'Connor, Barbara Pro, Tim Illidge, Michelle Fanale, Ranjana Advani, Nancy L Bartlett, Jacob Haaber Christensen, Franck Morschhauser, Eva Domingo-Domenech, Giuseppe Rossi, Won Seog Kim, Tatyana Feldman, Anne Lennard, David Belada, Árpád Illés, Kensei Tobinai, Kunihiro Tsukasaki, Su-Peng Yeh, Andrei Shustov, Andreas Hüttmann, Kerry J Savage, Sam Yuen, Swaminathan Iyer, Pier Luigi Zinzani, Zhaowei Hua, Meredith Little, Shangbang Rao, Joseph Woolery, Thomas Manley, Lorenz Trümper, David Aboulafia, Onder Alpdogan, Kiyoshi Ando, Luca Arcaini, Luca Baldini, Naresh Bellam, Nancy Bartlett, Dina Ben Yehuda, Fabio Benedetti, Peter Borchman, Dominique Bordessoule, Pauline Brice, Javier Briones, Dolores Caballero, Angelo Michele Carella, Hung Chang, June Weon Cheong, Seok-Goo Cho, Ilseung Choi, Sylvain Choquet, Andrei Colita, Angela Giovanna Congui, Francesco D'amore, Nam Dang, Kelly Davison, Sophie de Guibert, Peter de Nully Brown, Vincent Delwail, Judit Demeter, Francesco di Raimondo, Young Rok Do, Eva Domingo, Michael Douvas, Martin Dreyling, Thomas Ernst, Keith Fay, Silvia Fernandez Ferrero, Ian Winchester Flinn, Andres Forero-Torres, Christopher Fox, Jonathan Friedberg, Noriko Fukuhara, Jose Garcia-Marco, Jorge Gayoso Cruz, Jose Gomez Codina, Remy Gressin, Andrew Grigg, Ronit Gurion, Corinne Haioun, Roman Hajek, Mathias Hanel, Kiyohiko Hatake, Robert Hensen, Netanel Horowitz, Andreas Huttmann, Arpad Illes, Kenichi Ishizawa, Miguel Islas-Ohlmayer, Eric Jacobsen, Murali Janakiram, Wojciech Jurczak, Mark Kaminski, Koji Kato, Ilya Kirgner, Ching-Yuan Kuo, Mihaela Cornelia Lazaroiu, Katell Le Du, Jong-Seok Lee, Steven LeGouill, Paul LaRosee, Itai Levi, Brian Link, Herve Maisonneuve, Dai Maruyama, Jiri Mayer, John McCarty, Pam McKay, Yosuke Minami, Heidi Mocikova, Enrica Morra, Javier Munoz, Hirokazu Nagai, Owen O'Connor, Stephen Opat, Ruth Pettengell, Antonio Pezzutto, Michael Pfreundschuh, Andrzej Pluta, PierLuigi Porcu, Hang Quach, Alessandro Rambaldi, William Renwick, Ruben Reyes, Antonia Rodriguez Izquierdo, Jia Ruan, Chiara Rusconi, Gilles Salles, Armando Santoro, Jose Sarriera, Kerry Savage, Hirohiko Shibayama, Cheolwon Suh, Anna Sureda, Mitsune Tanimoto, Masafumi Taniwaki, Herve Tilly, Marek Trneny, Lorenz Trumper, Norifumi Tsukamoto, Umberto Vitolo, Jan Walewski, Eckhart Weidmann, Martin Wilhelm, Mathias Witzens-Harig, Abdulraheem Yacoub, Kazuhito Yamamoto, Sung-Soo Yoon, Hwan Jung Yun, Jasmine Zain
Publikováno v:
ECHELON-2 Study Group 2019, ' Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2) : a global, double-blind, randomised, phase 3 trial ', Lancet (London, England), vol. 393, no. 10168, pp. 229-240 . https://doi.org/10.1016/S0140-6736(18)32984-2
Horwitz, S, O'Connor, O A, Pro, B, Illidge, T, Fanale, M, Advani, R, Bartlett, N L, Christensen, J H, Morschhauser, F, Domingo-Domenech, E, Rossi, G, Kim, W S, Feldman, T, Lennard, A, Belada, D, Illés, Á, Tobinai, K, Tsukasaki, K, Yeh, S-P, Shustov, A, Hüttmann, A, Savage, K J, Yuen, S, Iyer, S, Zinzani, P L, Hua, Z, Little, M, Rao, S, Woolery, J, Manley, T, Trümper, L & ECHELON-2 Study Group 2019, ' Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2) : a global, double-blind, randomised, phase 3 trial ', Lancet, vol. 393, no. 10168, pp. 229-240 . https://doi.org/10.1016/S0140-6736(18)32984-2
Horwitz, S, O'Connor, O A, Pro, B, Illidge, T, Fanale, M, Advani, R, Bartlett, N L, Christensen, J H, Morschhauser, F, Domingo-Domenech, E, Rossi, G, Kim, W S, Feldman, T, Lennard, A, Belada, D, Illés, Á, Tobinai, K, Tsukasaki, K, Yeh, S-P, Shustov, A, Hüttmann, A, Savage, K J, Yuen, S, Iyer, S, Zinzani, P L, Hua, Z, Little, M, Rao, S, Woolery, J, Manley, T, Trümper, L & ECHELON-2 Study Group 2019, ' Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2) : a global, double-blind, randomised, phase 3 trial ', Lancet, vol. 393, no. 10168, pp. 229-240 . https://doi.org/10.1016/S0140-6736(18)32984-2
BACKGROUND: Based on the encouraging activity and manageable safety profile observed in a phase 1 study, the ECHELON-2 trial was initiated to compare the efficacy and safety of brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36b3b4862c5298b1ae704a6491430a8d
http://hdl.handle.net/20.500.11769/493757
http://hdl.handle.net/20.500.11769/493757
Autor:
Ian W. Flinn, Francine M. Foss, Mark Douglas, Nitin Jain, Kerstin Allen, Virginia Kelly, Manish Patel, Steven M. Horwitz, Jeffrey Jones, Susan O'Brien, Jan A. Burger, Pierluigi Porcu, Kerrie Faia, Jennifer Sweeney, Howard M. Stern, Brad S. Kahl, Patrick Kelly
Publikováno v:
Am J Hematol
Duvelisib (IPI-145), an oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-δ and -γ, was evaluated in a Phase 1 study in advanced hematologic malignancies, which included expansion cohorts in relapsed/refractory (RR) chronic lymphocytic leuke
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45e42534e31245adb66db84a8026ed87
https://europepmc.org/articles/PMC8260004/
https://europepmc.org/articles/PMC8260004/
Autor:
Mark Weiss, Lewis J. Rose, Sameh Gaballa, Matthew Carabasi, Michael Ramirez, Pierluigi Porcu, Onder Alpdogan, Neal Flomenberg, Sushil Ghimire, Joanne Filicko-O'Hara, Tingting Zhan, Ubaldo E. Martinez-Outschoorn, Jonathan Pan, Andrew E. Chapman, Barbara Pro, John L. Wagner
Publikováno v:
Blood. 134:5318-5318
Background Currently available salvage chemotherapy regimens for patients (pts) with relapsed or refractory (RR) aggressive B-cell non-Hodgkin lymphoma (NHL) are mostly inpatient regimens and offer comparable response rates. Bendamustine has single a
Autor:
Patrick Kelly, F. Foss, Manish Patel, Pierluigi Porcu, Ian W. Flinn, Kerstin Allen, Virginia Kelly, Mark Douglas, Jan A. Burger, Steven M. Horwitz, Yasuhiro Oki, Nitin Jain, Jennifer Sweeney, Jeffrey Jones, Susan O'Brien, Brad S. Kahl
Duvelisib is an oral dual inhibitor of phosphoinositide 3-kinase-δ (PI3K-δ) and PI3K-γ in late-stage clinical development for hematologic malignancy treatment. This phase 1 study evaluated maximum tolerated dose (MTD), pharmacokinetics, pharmacody
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e35e71ad9245f799755d0a16b278765a
https://europepmc.org/articles/PMC6033052/
https://europepmc.org/articles/PMC6033052/